KIT and systemic mastocytosis: Whereas survival and the quality of life (QOL) were poor in advanced SM until recently, the advent of new potent KIT D816V‐targeting drugs (midostaurin, avapritinib, others) and other potent therapies, including HSCT, has greatly improved progression‐free and overall survival in these patients [74, 83, 92].